Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research BRAF 

    • BRAF in metastatic melanoma 

    • Oncogenic BRAF in melanoma subtypes 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
      • RAF proteins in the RAS-RAF pathway
      • What is BRAF?
      • What is Oncogenic BRAF?
      • Oncogenic BRAF in cancer
      • BRAF in metastatic melanoma
        • Oncogenic BRAF in melanoma development
        • Oncogenic BRAF in melanoma subtypes
        • Oncogenic BRAF and prognosis
        • Identifying BRAF mutations in melanoma
      • References
      • Glossary
    • Research Cancer Immunotherapy
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Colorectal Cancer
    • Multiple Myeloma
    • Ovarian Cancer
  • Molecular Causes of Cancer
    • Evading growth suppressors
    • Inducing angiogenesis
    • Activating invasion and metastasis
    • Resisting cell death
  • Biological Pathways
    • Apoptosis
    • MAPK Signaling
  • Therapeutic Targets
    • MEK
  • Clinical Trials
    • Multiple Myeloma
  • Cancer Biomarkers
    • Multiple Myeloma
      • Receptor-Mediated Endocytosis
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
      • Receptor-Mediated Endocytosis
      • Anti-PDL1 (MPDL3280A)
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
    • Apoptosis
      • Emerging therapeutic options
    • Bispecific Monoclonal Antibodies
      • Emerging therapeutic options
    • Glycoengineered Antibodies
      • HER Signaling
      • Emerging therapeutic options
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
    • Non-Antibody Biologics
      • Apoptosis
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
    • Targeted Small Molecules
      • Apoptosis
      • MAPK Signaling
      • PI3K/Akt/mTOR Signaling
      • MEK Inhibitor (GDC-0973)
      • PI3K Inhibitor (GDC-0941)
      • Glossary
      • Resisting apoptosis
      • Emerging therapeutic options
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
      • Slide decks and videos
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
      • Melanoma
      • Multiple Myeloma
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • HER Signaling
      • Anti-PDL1 (MPDL3280A)
      • Emerging therapeutic options
      • Inhibition of HER2 dimerization
      • HER2:HER3 dimer
      • Glossary
      • HER1/EGFR evaluation
      • HER1/EGFR in lung cancer
      • HER1/EGFR in pancreatic cancer
      • HER1/EGFR and prognosis
      • Summary
      • HER1/EGFR as a therapeutic target
      • HER2 in breast cancer
      • HER2 detection methods
      • HER2 dysregulation
      • HER2
      • HER2 in ovarian cancer
      • HER2 and prognosis
      • Summary
      • HER2 as a therapeutic target
      • HER3 in breast cancer
      • HER3 dysregulation
      • HER3 evaluation
      • HER3
      • HER3 in ovarian cancer
      • Summary
      • HER3 as a therapeutic target
      • HER4
      • HER pathways slide decks and videos
      • Receptor activation
      • Cancer effects
      • Dimerization
      • Overview
      • HER ligands
      • HER receptors
      • Summary
      • Therapeutic potential of HER pathways
      • Research MET
      • What is Met?
      • Glossary
      • Slide decks and videos
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
      • Melanoma
Share

Oncogenic BRAF is expressed in a variety of melanoma subtypes

Historically, the classification of primary melanoma has been determined by site of origin, tumor thickness, and histological subtype. For instance, cutaneous melanoma, a primary site of melanoma, has been subclassified into 4 groups with distinct clinicopathologic features: superficial spreading, nodular, lentigo maligna, and acral lentiginous melanoma (Figure 2).17

Ongoing genetic studies using a variety of technologies, including DNA sequencing and immunohistochemistry, are demonstrating specific genotype-phenotype correlations that provide insights into molecular subclassifications of melanoma and the heterogeneous nature of this malignancy.17

Continuing research into determining whether molecular pathways of tumor progression differ between subtypes of cutaneous melanoma is critical in order to ensure the most appropriate treatments can be offered to the right patient subtype.24

Superficial spreading malignant melanomas and lentigo maligna melanomas

A study by Saldanha et al concluded that while the mutational frequency of BRAF differed between cutaneous melanoma subtypes, BRAF mutations were most frequent in superficial spreading malignant melanomas and lentigo maligna melanomas. Superficial spreading melanoma is commonly associated with sun exposure and comprises 70% of primary cutaneous melanomas. Lentigo maligna melanomas are diagnosed as thin lesions and commonly manifest on the faces of older individuals. Identification of BRAF mutations in these patients suggests that the activation of the RAS-RAF pathway may be an important genetic feature of these melanomas.15,25

Figure 2

A.
Figure 2.B

Reprinted with permission from MacMillan Publishers Ltd: Mod Pathol, 2006.

B.
Figure 2.D

Reprinted with permission from MacMillan Publishers Ltd: Mod Pathol, 2006.

A) Histology of superficial spreading melanoma comprises haphazardly distributed atypical melanocytes present as single cells and/or nests of cells throughout different levels of the epidermis. B) Histology of lentigo maligna. The tumor is typically characterized by confluent single melanocytes aligned along the dermal-epidermal junction and spreading down cutaneous appendages. The cells are small and do not normally exhibit hyperchromatic nuclei and pagetoid extensions. An underlying solar elastosis is common in this subcategory of tumors.26,27

 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: Oncogenic BRAF and prognosis »

© 2011 Genentech USA, Inc. All rights reserved